{"type":"trials","record":{"id":42271,"source_id":"clinicaltrials-gov","external_id":"NCT04919096","title":"Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration","brief_summary":"This is a Phase 1, randomized, double-masked, multicenter, parallel-assignment, pilot study to evaluate the safety, tolerability, initial clinical effectiveness, pharmacokinetics (PK), and immunogenicity of SCB-420 as compared with Eylea (aflibercept), in subjects with Neovascular Age-related Macular Degeneration. A total of 20 subjects with Neovascular Age-related Macular Degeneration will be enrolled across up to 11 sites in 3 countries (Australia, New Zealand, and China). The study will be conducted in 2 parts - Sentinel Safety Cohort and Open Enrolment. Subjects will be administered with 2 mg of SCB-420 or Eylea via intravitreal (IVT) injection every 4 weeks for a total 3 doses.","overall_status":"Withdrawn","phases":["PHASE1"],"study_type":"INTERVENTIONAL","sponsor":"Clover Biopharmaceuticals AUS Pty","enrollment":0,"countries":[],"start_date":"2022-04-01","completion_date":"2023-01-01","last_update_date":"2022-04-19","source_url":"https://clinicaltrials.gov/study/NCT04919096","editorial_summary":"A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":"Aflibercept","organization":"Clover Biopharmaceuticals, Ltd","interventions":["SCB-420","Aflibercept"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Incidence of ocular and non-ocular adverse events. — Baseline to Week 12","Change from baseline in Best Corrected Visual Acuity (BCVA) — Baseline to Week 12","Change in central foveal thickness (CFT) — Baseline to Week 12","Percentage Change from baseline in the area of Choroidal neovascularization (CNV) lesions in Neovascular Age-related Ma…","Observe serum concentration of free and total SCB 420 and Eylea — Baseline to Week 8","Observe maximum concentration (Cmax) of free and total SCB 420 and Eylea — Baseline to Week 8","Observe minimum concentration (Cmin) of free and total SCB 420 and Eylea — Baseline to Week 8","Observe Time to Maximum concentration (Tmax) of free and total SCB 420 and Eylea — Baseline to Week 8","Observe Elimination Half Life (T1/2) of free and total SCB 420 and Eylea — Baseline to Week 8","Titer of anti-drug antibodies (ADAs) against SCB-420 and Eylea at predose on Day 1, Week 4, and Week 8 — Baseline to We…","Neutralizing antibodies testing in confirmed ADA positive subjects — Baseline to Week 8"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Wet Age-related Macular Degeneration","SCB-420","Aflibercept"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04919096","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-04-01 to 2023-01-01","comparator":"Aflibercept","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.944Z","intervention":["SCB-420","Aflibercept"],"participants":0,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Incidence of ocular and non-ocular adverse events. — Baseline to Week 12","Change from baseline in Best Corrected Visual Acuity (BCVA) — Baseline to Week 12","Change in central foveal thickness (CFT) — Baseline to Week 12","Percentage Change from baseline in the area of Choroidal neovascularization (CNV) lesions in Neovascular Age-related Ma…","Observe serum concentration of free and total SCB 420 and Eylea — Baseline to Week 8","Observe maximum concentration (Cmax) of free and total SCB 420 and Eylea — Baseline to Week 8","Observe minimum concentration (Cmin) of free and total SCB 420 and Eylea — Baseline to Week 8","Observe Time to Maximum concentration (Tmax) of free and total SCB 420 and Eylea — Baseline to Week 8","Observe Elimination Half Life (T1/2) of free and total SCB 420 and Eylea — Baseline to Week 8","Titer of anti-drug antibodies (ADAs) against SCB-420 and Eylea at predose on Day 1, Week 4, and Week 8 — Baseline to We…","Neutralizing antibodies testing in confirmed ADA positive subjects — Baseline to Week 8"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42271","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}